


## HLA-A\*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population

Byung-Keun Kim, MD <sup>\*†‡</sup> · Jae-Woo Jung, MD, PhD <sup>‡</sup> · Tae-Bum Kim, MD, PhD <sup>§</sup> · Sang Kun Lee, MD, PhD <sup>#, \*\*</sup> · Hye-Ryun Kang, MD, PhD <sup>\*†</sup> · Heung-Woo Park, MD, PhD <sup>\*†</sup>  ... Show more[Affiliations & Notes](#) [Article Info](#)  Get Access Cite Share Set Alert Get Rights Reprints[Previous article](#) [Next article](#) 


Show Outline

Lamotrigine (LTG) was first synthesized in the early 1980s and approved by the US Food and Drug Administration in 1994. Since then, it has been used worldwide as an effective anticonvulsant and as a mood stabilizer. However, LTG can cause adverse reactions including cutaneous adverse drug reactions with approximately 10% probability.<sup>1</sup> Severe cutaneous adverse reactions (SCARs) are the most serious form and include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS). Although SCAR is clinically important because of its high mortality, there are currently no predictive markers for LTG-induced SCAR. Recent advances in pharmacogenomics have found that certain HLA alleles are significantly associated with SCARs caused by drugs, such as carbamazepine and allopurinol.<sup>2-4</sup> In addition, several studies have described the economic efficiency of genetic screening before prescribing a specific drug.<sup>3</sup> Based on these findings, we performed HLA genotyping to identify HLA alleles associated with the risk for LTG-induced SCAR in a Korean population.


**Annals**  
of Allergy, Asthma & Immunology

## Get full text access

Log in, subscribe or purchase for full access.

 Get Access

## References

1. Moon, J. · Park, H.K. · Chu, K. ...  
**The HLA-A\*24:02/Cw\*01:02 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population**  
*Epilepsia*. 2015; **56**:e161-e167  
[Crossref](#) [Scopus \(45\)](#) [PubMed](#) [Google Scholar](#)
2. Kim, S.H. · Lee, K.W. · Song, W.J. ...  
**Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans**  
*Epilepsy Res*. 2011; **97**:190-197  
[Full Text](#)  [Full Text \(PDF\)](#) [Scopus \(228\)](#) [PubMed](#) [Google Scholar](#)
3. Chen, Z. · Liew, D. · Kwan, P.  
**Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions**  
*PLoS One*. 2014; **9**:e96990  
[Crossref](#) [Scopus \(19\)](#) [PubMed](#) [Google Scholar](#)
4. Lonjou, C. · Borot, N. · Sekula, P. ...  
**A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs**  
*Pharmacogenet Genomics*. 2008; **18**:99-107  
[Crossref](#) [Scopus \(555\)](#) [PubMed](#) [Google Scholar](#)
5. Eshki, M. · Allamore, L. · Musette, P. ...  
**Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure**  
*Arch Dermatol*. 2009; **145**:67-72  
[Crossref](#) [Scopus \(252\)](#) [PubMed](#) [Google Scholar](#)
6. Lee, K.W. · Oh, D.H. · Lee, C. ...  
**Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population**  
*Tissue Antigens*. 2005; **65**:437-447  
[Crossref](#) [Scopus \(181\)](#) [PubMed](#) [Google Scholar](#)
7. Zeng, T. · Long, Y.S. · Min, F.L. ...  
**Association of HLA-B\*15:02 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis**  
*Int J Dermatol*. 2015; **54**:488-493  
[Crossref](#) [Scopus \(45\)](#) [PubMed](#) [Google Scholar](#)
8. Kazeem, G.R. · Cox, C. · Aponte, J. ...  
**High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients**




## Article metrics

34

Citations

20

Captures

[View details](#) 

## Related articles (40)


ADDRESSING A SEVERE CUTANEOUS ADVERSE DRUG REACTION (SCAR) IN A NEWBORN

Salih et al.  
*Annals of Allergy, Asthma & Immunology*

Drug patch testing for severe cutaneous adverse reactions: Not in the United States?

Whitley et al.  
*Annals of Allergy, Asthma & Immunology*

Drug-induced severe cutaneous adverse reactions: Determine the cause and prevention

Zhang et al.  
*Annals of Allergy, Asthma & Immunology*, August 7, 2019[Show more](#) 

9. Fricke-Galindo, I. · Martinez-Juarez, I.E. · Monroy-Jaramillo, N. ...  
**HLA-A\*02:01:01/-B\*35:01:01/-C\*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients**  
*Pharmacogenomics*. 2014; 15:1881-1891  
[Crossref ↗](#) [Scopus \(47\) ↗](#) [PubMed ↗](#) [Google Scholar ↗](#)

10. Naisbitt, D.J. · Farrell, J. · Wong, G. ...  
**Characterization of drug-specific T cells in lamotrigine hypersensitivity**  
*J Allergy Clin Immunol*. 2003; 111:1393-1403  
[Full Text ↗](#) [Full Text \(PDF\) ↗](#) [Scopus \(191\) ↗](#) [PubMed ↗](#) [Google Scholar ↗](#)

[View full text](#)

<a href="#">Home</a>	<a href="#">Articles in Press</a>	<a href="#">Author Information</a>	<a href="#">About Open Access</a>	<a href="#">Reprints</a>
<a href="#">Access for Developing Countries</a>	<a href="#">Current Issue</a>	<a href="#">Permissions</a>	<a href="#">Activate Online Access</a>	<a href="#">New Content Alerts</a>
<a href="#">Editor's Choice</a>	<a href="#">List of Issues</a>	<a href="#">Researcher Academy</a>	<a href="#">Career Opportunities</a>	<a href="#">Subscribe</a>
<a href="#">Issue PPT</a>	<a href="#">Supplements</a>	<a href="#">Submit a Manuscript</a>	<a href="#">Contact Information</a>	<b>MORE PERIODICALS</b>
<a href="#">Ocular Allergy</a>	<a href="#">News Archive</a>	<a href="#">CME</a>	<a href="#">Editorial Board</a>	<a href="#">Find a Periodical</a>
<a href="#">Allergen of the Month</a>	<b>FOR AUTHORS</b>	<b>JOURNAL INFO</b>	<a href="#">Information for Advertisers</a>	<a href="#">Go to Product Catalog</a>
<b>ARTICLES &amp; ISSUES</b>	<a href="#">About Open Access</a>	<a href="#">About the Journal</a>	<a href="#">Pricing</a>	

The content on this site is intended for healthcare professionals.

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the [Cookie settings](#) | [Your Privacy Choices](#) for this site.

All content on this site: Copyright © 2025 Elsevier Inc., its licensors, and contributors.  
All rights are reserved, including those for text and data mining, AI training, and similar technologies.  
For all open access content, the relevant licensing terms apply.

[Privacy Policy](#) [Terms and Conditions](#) [Accessibility](#) [Help & Contact](#)

